Aleniglipron’s tolerability could be a differentiator for Structure Therapeutics, but its efficacy lags competitors. Read why ...

Fortune has partnered with Indiggo to measure Return On Leadership, called the ROL100. Read which dividend stocks we ...

Key Takeaways Novo Nordisk stock rose on Tuesday after the Financial Times reported that an activist investor is building a ...

Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living ...

Hims & Hers Health Inc (NYSE:HIMS) stock fell 3.8% Tuesday after Eli Lilly and Company (NYSE:LLY) indicated it would not partner with telehealth firms selling copycat versions of weight-loss drugs, ...

The market seems to share this optimistic view, since Eli Lilly and has a short interest of only 0.9% (this is the percentage ...

UBS is holding firm on its Buy rating and $1,050 price target for Eli Lilly, driven by faith in the upcoming SURPASS-CVOT ...

The World Bank on Tuesday slashed its global growth forecast for 2025 by four-tenths of a percentage point to 2.3%, saying ...

There's no peak in global oil demand on the horizon and it will take trillions in investment in the coming decades to meet ...

The companies said they would launch public-road trials of fully autonomous vehicles in the U.K. capital as part of Uber's pans to bring the technology to Europe. J.M. Smucker Sales Decline, Swings to ...

The diabetic nephropathy market is driven by the growing burden of diabetes and the increasing demand for effective treatments for kidney disease. Advances in therapeutics, including new drug classes ...

US stocks finished higher on Tuesday as optimism rose that Beijing and Washington are making progress in their pivotal trade ...